FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379981938> ?p ?o ?g. }

• W4379981938 endingPage "312" @default.
• W4379981938 startingPage "311" @default.
• W4379981938 abstract "Introduction: Mature T and NK-cell lymphomas represent a heterogeneous group of rare lymphoid disorders arising from mature T cells of post-thymic origin. The T-cell Project 2.0 (TCP2) was launched in 2018 with the aim of better understanding this group of rare disorders, capturing a real-life snapshot of the evolving landscape of T-cell lymphoma biology, treatment strategies, and outcome. Here we report preliminary data on histotype distribution, disease characteristics, front line treatment, and short-term outcome of patients registered between 2018 and 2021. Methods: The TCP2 (ClinicalTrials.gov Identifier: NCT03964480) is a prospective, longitudinal, international, observational study of patients with Peripheral T-cell lymphoma (PTCL). For this analysis we considered cases based on the diagnosis made locally according to the WHO2016 classification. The study was approved by each participating center and required patients to sign informed consent. Results: Between October 2018 and December 2021, 741 eligible cases with newly diagnosed PTCLs were registered by 94 Institutions across 17 Countries. Overall, PTCL-NOS, AITL, ALCL ALK-, ALCL ALK+, ENKTCL, and ATLL resulted the most frequent 6 subtypes, accounting for 91% of cases, while the remaining 9% were represented by few cases of 13 different subtypes. Of note, only 16 cases (2.1%) were classified according to entities not considered in the previous WHO 2008 classification. The median age at diagnosis was 57 years (18–93), 56.5% of patients were male, the presence of systemic symptoms was reported in 30% of cases, 7.4% had ECOG-PS 3–4, 71% advanced disease and 36.6% bone marrow involvement. Overall, 88% were treated with combination chemotherapy and 28% of patients with advanced stage disease in complete or partial remission after chemotherapy were consolidated with high dose therapy and stem cell transplantation. After a median follow-up of 21 months, the 2-year PFS and OS of the whole series were 38% and 52%, respectively. At the same time point, the PFS and OS (in brackets) were: PTCL-NOS (24% and 43%); AITL (40% and 50%); ENKTL (44% and 53%); ALCL ALK- (52% and 67%); ALCL ALK+ (71% and 85%) and ATLL (14% and 27%). Comparing the distribution of cases enrolled in the present study with those in the previous TCP1 (2008–2018), we found a 6% and 3% decrease in the frequency of PTCL-NOS and EATL, respectively, whilst the frequency of other histotypes remained almost unchanged. Of note, no statistically significant differences emerged in terms of PFS and OS for the comparable histotypes of TCP1 and TCP2. Conclusions: Based on the analysis of this large series of cases of PTCL prospectively registered in the TCP2, it seems “Nothing new under the sun”: no improvement in terms of outcome and a very limited effect of the WHO2016 in classification of cases in the real world. The research was funded by: Angela Serra Association for Cancer Research Keywords: Aggressive T-cell non-Hodgkin lymphoma, Pathology and Classification of Lymphomas No conflicts of interests pertinent to the abstract." @default.
• W4379981938 created "2023-06-10" @default.
• W4379981938 creator A5006007579 @default.
• W4379981938 creator A5006324385 @default.
• W4379981938 creator A5008129100 @default.
• W4379981938 creator A5010085553 @default.
• W4379981938 creator A5011910526 @default.
• W4379981938 creator A5016787940 @default.
• W4379981938 creator A5016803459 @default.
• W4379981938 creator A5020548534 @default.
• W4379981938 creator A5023781725 @default.
• W4379981938 creator A5028412728 @default.
• W4379981938 creator A5035398527 @default.
• W4379981938 creator A5049025385 @default.
• W4379981938 creator A5051528298 @default.
• W4379981938 creator A5059140269 @default.
• W4379981938 creator A5060314041 @default.
• W4379981938 creator A5067147178 @default.
• W4379981938 creator A5069406522 @default.
• W4379981938 creator A5075582709 @default.
• W4379981938 creator A5080156532 @default.
• W4379981938 creator A5080373697 @default.
• W4379981938 creator A5082634742 @default.
• W4379981938 creator A5087852699 @default.
• W4379981938 creator A5090964554 @default.
• W4379981938 date "2023-06-01" @default.
• W4379981938 modified "2023-10-18" @default.
• W4379981938 title "Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0." @default.
• W4379981938 doi "https://doi.org/10.1002/hon.3164_218" @default.
• W4379981938 hasPublicationYear "2023" @default.
• W4379981938 type Work @default.
• W4379981938 citedByCount "0" @default.
• W4379981938 crossrefType "journal-article" @default.
• W4379981938 hasAuthorship W4379981938A5006007579 @default.
• W4379981938 hasAuthorship W4379981938A5006324385 @default.
• W4379981938 hasAuthorship W4379981938A5008129100 @default.
• W4379981938 hasAuthorship W4379981938A5010085553 @default.
• W4379981938 hasAuthorship W4379981938A5011910526 @default.
• W4379981938 hasAuthorship W4379981938A5016787940 @default.
• W4379981938 hasAuthorship W4379981938A5016803459 @default.
• W4379981938 hasAuthorship W4379981938A5020548534 @default.
• W4379981938 hasAuthorship W4379981938A5023781725 @default.
• W4379981938 hasAuthorship W4379981938A5028412728 @default.
• W4379981938 hasAuthorship W4379981938A5035398527 @default.
• W4379981938 hasAuthorship W4379981938A5049025385 @default.
• W4379981938 hasAuthorship W4379981938A5051528298 @default.
• W4379981938 hasAuthorship W4379981938A5059140269 @default.
• W4379981938 hasAuthorship W4379981938A5060314041 @default.
• W4379981938 hasAuthorship W4379981938A5067147178 @default.
• W4379981938 hasAuthorship W4379981938A5069406522 @default.
• W4379981938 hasAuthorship W4379981938A5075582709 @default.
• W4379981938 hasAuthorship W4379981938A5080156532 @default.
• W4379981938 hasAuthorship W4379981938A5080373697 @default.
• W4379981938 hasAuthorship W4379981938A5082634742 @default.
• W4379981938 hasAuthorship W4379981938A5087852699 @default.
• W4379981938 hasAuthorship W4379981938A5090964554 @default.
• W4379981938 hasBestOaLocation W43799819381 @default.
• W4379981938 hasConcept C126322002 @default.
• W4379981938 hasConcept C143998085 @default.
• W4379981938 hasConcept C2777547418 @default.
• W4379981938 hasConcept C2777589544 @default.
• W4379981938 hasConcept C2777872185 @default.
• W4379981938 hasConcept C2779338263 @default.
• W4379981938 hasConcept C71924100 @default.
• W4379981938 hasConceptScore W4379981938C126322002 @default.
• W4379981938 hasConceptScore W4379981938C143998085 @default.
• W4379981938 hasConceptScore W4379981938C2777547418 @default.
• W4379981938 hasConceptScore W4379981938C2777589544 @default.
• W4379981938 hasConceptScore W4379981938C2777872185 @default.
• W4379981938 hasConceptScore W4379981938C2779338263 @default.
• W4379981938 hasConceptScore W4379981938C71924100 @default.
• W4379981938 hasIssue "S2" @default.
• W4379981938 hasLocation W43799819381 @default.
• W4379981938 hasOpenAccess W4379981938 @default.
• W4379981938 hasPrimaryLocation W43799819381 @default.
• W4379981938 hasRelatedWork W170895960 @default.
• W4379981938 hasRelatedWork W1972179222 @default.
• W4379981938 hasRelatedWork W2110877204 @default.
• W4379981938 hasRelatedWork W2205257049 @default.
• W4379981938 hasRelatedWork W2416652311 @default.
• W4379981938 hasRelatedWork W2935188226 @default.
• W4379981938 hasRelatedWork W2937428028 @default.
• W4379981938 hasRelatedWork W3015415984 @default.
• W4379981938 hasRelatedWork W3131095990 @default.
• W4379981938 hasRelatedWork W4281705095 @default.
• W4379981938 hasVolume "41" @default.
• W4379981938 isParatext "false" @default.
• W4379981938 isRetracted "false" @default.
• W4379981938 workType "article" @default.